China Suspends Sale of Leukemia Drug Made by Shanghai Company (China)
This article was originally published in PharmAsia News
Executive Summary
China's State Food and Drug Administration (SFDA) has suspended the sales of leukemia treatment drug methotrexate made by Shanghai Hualian Pharmaceutical because of health concerns about using it with children. The drug has caused serious adverse reactions in several leukemia child patients in three hospitals of Guangxi Zhuang Autonomous Region and Shanghai. Local SFDA officials now will review the drug. (Click here for more